INSIDE PHARMCENTRIC

SERIES
INTRODUCTION

PHARMCENTRIC
ADVISORS


ARTICLES AND WHITEPAPERS


RESOURCES

CONTACT US

HOME


JOIN OUR MAILING LIST


JOIN OUR E-MAIL LIST



E-MAIL INQUIRIES

 

 

 

 

 

 

Distinguished Advisory Board

Edward Arcuri
Senior Vice President, Operations and COO
Aviron
 



Jeff Antos
President, Beacon Hill Technologies, Inc.

Jeff Antos is the president of Beacon Hill Technologies, a software and consulting company founded in 1989 in Boston. Over the past ten years, he has coached numerous IT and drug development teams for a variety of companies. Jeff's background includes management and executive positions at Procter & Gamble, Hewlett-Packard, Stanford Research, CSC, and several start-ups. He received a B.S. in mechanical engineering from Union College, and attended Albany Medical College in New York. He has created a variety of intellectual properties; in addition to numerous software programs, Jeff was recently issued a patent for an Internet convergence device. Jeff frequently speaks to business groups on the use of cross-functional teams to achieve superior business results. In addition, he publishes a quarterly electronic newsletter on this topic.

Jane Bainbridge
Vice President, Global Project Manager
Pharmacia Corporation

Graduated from University of Surrey, Guildford, UK with a Bachelors in Biochemistry (Toxicology) (1984) and a Masters in Toxicology (1987). Pharmaceutical career began in Regulatory Affairs with Sterling Winthrop in 1988. Around the time of the merger with Eastman Kodak joined the Regulatory group of Rhone-Poulenc, soon to become Rhone-Poulenc Rorer. In 1991 emigrated to Australia and joined the Regulatory Affairs team at Parke Davis, Sydney. In 1993 joined the Regulatory team at Pharmacia, shortly to become Pharmacia & Upjohn. In 1997 transferred with Pharmacia & Upjohn to the R&D site in Stockholm to lead the Regulatory team there. In 1999 transferred within Pharmacia & Upjohn to Project Leadership / Project Management and in January 2000 relocated to Peapack, NJ. Currently lead the Global Project Management group based on Pharmacia's R&D sites in Europe and the US.

Lisa Cowell
V.P. Business Development
Affymetrix


Gary C. Cupit, Pharm.D.
Vice President, Global Business Development and Licensing
Novartis Pharmaceuticals
 
Gary is currently Vice President, Global Business Development and Licensing, Novartis Pharmaceuticals. He has more than 15 years of pharmaceutical and healthcare industry experience in addition to 14 years in university-based academics in clinical pharmacy. Prior to joining Novartis, Gary held positions in Business Development at Knoll Pharmaceutical and was Vice President, Cardiovascular Business Unit with The Medicines Company of Cambridge, MA. Gary has also worked at SmithKline Beecham(SB) Pharmaceuticals in a number of capacities in product management (Tagamet, Hycamtin), new product development and sales. Gary received his Bachelor of Science in Pharmacy from the Medical College of Virginia and Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science.

Robert J. Franco, Ph.D.
Director
PRTM
 

Janet Foulkes
Sr. Director/Group Leader
MSO Pfizer, Inc.
 


Charles T. Gombar, Ph.D.
Senior Director, Project Management Neuroscience
Wyeth-Ayerst Research

Dr. Gombar is currently Senior Director, Project Management, Neuroscience at Wyeth-Ayerst Research responsible for management of the Neuroscience portfolio within R&D and for leading specific project teams. Dr. Gombar joined Wyeth-Ayerst in 1997. Prior to joining Wyeth-Ayerst, Dr. Gombar held Project Director positions at SmithKline Beecham, Sterling-Winthrop, and Knoll Pharmaceutical Co. leading project teams in cardiovascular, inflammatory, oncology and CNS therapeutic areas. Before embarking on a career in Project Management Dr. Gombar held positions of increasing responsibility in the Drug Metabolism department at SmithKline. He received his Ph.D. in Pharmacology from the Albany Medical College and was a postdoctoral fellow at the Fels Research Institute at Temple University. Dr. Gombar has been active in professional organizations serving on program committees for the PMA Project Management & Finance subsection annual meeting, was a founding member and chair of the DIA Project Management Special Interest Advisory Committee, and is currently serving on an advisory board for development of a new conference on drug development for the Tufts Center for Drug Development.

Douglas Green, M.D.
Exec. V.P. Clinical Development
Merck & Co, Inc.

Derek W. Hodkey
Senior Director, Project Management and Strategic Planning
Vertex Pharmaceuticals, Inc.
 


Susan T. Hall, Ph.D.
U.S. Site Director, World Wide Project Planning
GlaxoSmithKline

Dr. Sue Hall is a Ph.D. Pharmacologist/Pharmacokineticist from the University of Manchester, England. She joined the Pharmaceutical Industry in 1984 with Beecham Pharmaceuticals in the U.K. as a pharmacokineticist. Then, in 1986, she moved to Glaxo where she worked in the Clinical Pharmacology Department for 6 years in the U.K. before transferring to the U.S. department in 1992. In 1993, she joined the international department of Project Planning with Glaxo in the U.S. She has held positions of increasing seniority within this organisation, including in 1997, establishing and leading a specialized regional planning group supporting U.S. Marketing and Medical Affairs/Phase IV studies and then in 1999 was appointed U.S. Site Director providing planning support for international, cross-functional teams from Research through to Commercial. She is now Operations Director for Metabolic and Musculoskeletal Product Development in GlaxoSmithKline Project Management and R&D Strategy.

Kenneth I. Kaitin, Ph.D.
Director
Tufts Center for the Study of Drug Development

Dr. Kaitin is the Director of the Tufts Center for the Study of Drug Development at Tufts University, where he studies national and worldwide trends in pharmaceutical innovation, regulation, and public policy. He is also Assistant Professor of Pharmacology and Experimental Therapeutics at Tufts University School of Medicine. Dr. Kaitin has written extensively on factors that contribute to the slow pace and high cost of pharmaceutical R&D, and the impact of regulatory and legislative initiatives to speed drug development and approval. His articles have been published widely in medical and policy journals.

Dr. Kaitin has provided testimony before the U.S. Congress in hearings on FDA reform, and he has worked closely with the U.S. Council on Competitiveness in the preparation of their report on the pharmaceutical industry. He is a former President of the Drug Information Association, and he serves on the faculty of the European Center for Pharmaceutical Medicine. He is a member of the American Society for Clinical Pharmacology and Therapeutics, the New York Pharma Forum, the Drug Information Association, and Regulatory Affairs Professionals, and serves on the editorial boards of the American Journal of Therapeutics, Clinical Research and Regulatory Affairs, and the Drug Information Journal. Dr. Kaitin received a B.S. from Cornell University and an M.S. and Ph.D. in pharmacology from the University of Rochester.

Alan Marchington
Vice President, Productivity
Millennium Pharmaceuticals

 


William D. Matthews, Ph.D.
Vice President, Project Management & Portfolio Planning
Centocor

William Matthews received his Ph.D. in Pharmacology from Penn State University College of Medicine in 1976. After a Postdoctoral Fellowship, he joined Smith Kline and French Laboratories in 1977 as a research scientist in the cardiovascular disease area. William moved through various levels of increasing responsibility within the SK&F Research organization and in 1984 accepted the position of Director, Investigative Toxicology. In 1988 he was appointed Senior Director, Project Management and became Vice President, Project Management for SmithKlineBeecham Pharmaceuticals in 1990. In 1991 William was appointed Vice President and Therapeutic Area Head for Cardiopulmonary Development at SmithKlineBeecham. In 1997 he was seconded to the US Business as Director, New Product Development. In 1999 William was appointed Vice President, Project Management and Therapeutic Area Head for Novartis Pharmaceuticals with responsibility for cardiovascular, metabolism, diabetes, anti-infective and immunology products. William joined Centocor in his present position as of May 2001. He currently has responsibility for Project Management and Portfolio Management functions for Centocor R&D.

John W. Palmer
Senior Vice President, Program Management
Biogen, Inc.

John W. Palmer is Senior Vice President, Program Management at Biogen, Inc. He has been with Biogen since 1989, also serving as Program Executive, Director of Operations and Director of Marketing and Business Development. Prior to joining Biogen, Mr. Palmer held management positions at General Foods Corporation and at the Washington, D.C.-based consulting firm, Strategic Planning Associates and was co-founder of a medical air transport company. Mr. Palmer holds an MBA degree from The Wharton School at the University of Pennsylvania, and previously served five years as a commissioned office in the Regular Army with the 101st Airborne Division.